Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
PRINCETON, N.J., May 07, 2024--Bristol Myers Squibb to Participate in Upcoming Investor Conferences
PRINCETON, N.J., May 06, 2024--U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)